FeesSafety
Pluang+

Reed's schedules Q3 2026 earnings call for Nov 11 to discuss financial results.

Company Fundamentals
29 Oct 2026, 15:00 WIB
GlobeNewsWire
View Source
Neutral
Reed's schedules Q3 2026 earnings call for Nov 11 to discuss financial results.

Reed's, Inc., a leading maker of natural ginger beverages, announced it will hold a conference call on November 11, 2026, at 8:30 a.m. ET to discuss its financial results for Q3 and the first nine months of 2026. The company will release its earnings report before the call, which will include a Q&A session with management. This event provides investors insight into Reed's recent performance and outlook.

Reed's upcoming Q3 2026 conference call is the subject, with Pluang's Consumer Staples sector data providing market context. Of 63 US Consumer Staples stocks priced on Pluang, 53 gained and 8 declined as of Oct 29, 2026 18:41 WIB. Hershey Co (HSY) fell 3.29% with 100% sell orders and a typical hold time of 137 days, contrasting with TAL Education Group (TAL) and Ambev S.A. (ABEV), which both dropped less than 3.2% but had 100% buy orders and much shorter hold times of 6 and 5 days respectively.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App